In HIV-1 infected treatment-naïve patients with mild to moderate renal impairment (creatinine clearance [CrCl]: 50-89 mL/min), elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB, n=33) achieved high rates of virologic success [78.8%; 95% CI: 61.1% to 91.0%] and was well tolerated through Week 48. Four patients discontinued study drug due to an adverse event, none due to proximal renal tubulopathy. As expected, decreases in CrCl were noted as early as Week 2, after which they stabilized. The renal safety profile of STB in patients from this study is consistent with the long-term experience in a large number of patients with CrCl ≥ 70 mL/min.
treatment naïve patients with mild to moderate renal impairment (CrCl 50 to 89 mL/min) through Week 48.
Methods: Study Design and Patients
Study GS-US-236-0118 is a 96-week, phase 3, open-label, multicenter, two cohort study to evaluate the safety and efficacy of COBI-containing regimens in HIV-1 infected adult patients who are either treatment-naïve (STB cohort) or treatment-experienced (COBI cohort: switch ritonavir to COBI) with stable, mild to moderate renal impairment. As the two cohorts are distinct and not comparable (treatment-naïve versus -experienced), only the STB cohort (treatment naïve patients) is presented in this report. Eligibility criteria included no prior use of antiretroviral agents, HIV-1 RNA ≥ 1000 copies/mL regardless of CD4 cell count, genotype showing sensitivity to FTC and TDF, and stable renal function as determined by the investigator, with CrCl 50 to 89 mL/min for at least 6 months prior to the screening visit. The study was conducted in accordance with the Declaration of Helsinki. The protocol was reviewed and approved by central or site-specific institutional review boards or ethics committees. All participants gave written informed consent.
Procedures
Laboratory analyses (hematology, urinalysis and chemistry), including HIV-1 RNA and CD4 cell count, estimation of CrCl, and complete or symptom-directed physical examinations were performed at screening, baseline, and all subsequent study visits. Patients returned for study visits at Weeks 2, 4, 8, 12, 16, 24, 32, 40 , and 48. Following a confirmed virologic rebound (HIV-1 RNA ≥400 copies/mL or > 1 log 10 increase from nadir) or confirmed suboptimal virologic response (HIV-1 RNA ≥ 50 copies/mL and < 1 log 10 reduction from baseline by Week 8), confirmatory samples were sent for HIV-1 genotype and phenotype testing against protease, reverse transcriptase and integrase using PhenoSense GT, PhenoSense Integrase, and GeneSeq Integrase assays (Monogram Biosciences). The renal criterion for potential study drug discontinuation was CrCl < 50 mL/min confirmed within 7 days, and > 20% decrease in cystatin C-based estimated GFR (eGFR) at the confirming visit. The use of the latter is to have an assessment of eGFR that is not affected by inhibition of renal tubular creatinine secretion by COBI.
Statistical Analysis
Efficacy assessments included all patients who received at least 1 dose of study drug. The primary efficacy endpoint was the percentage of patients with HIV-1 RNA < 50 copies/mL at Week 24 as defined by the Food and Drug Administration (FDA) snapshot analysis algorithm; the percentage of patients and the associated 95% confidence intervals (CIs) were determined.
Secondary efficacy endpoints included: the percentage of patients with HIV-1 RNA < 50 copies/mL at Week 48 by snapshot, missing = failure, and missing = excluded, and the change from baseline in CD4 cell count.
Safety assessments were summarized for the safety analysis set, which included all patients who received at least 1 dose of study drug. Selected safety endpoints were summarized by baseline CrCl (< 70 mL/min and ≥70 mL/min). The primary renal endpoints included the change from baseline at Week 24 in the following parameters: CrCl; eGFR using Modification of Diet in Renal Disease (MDRD); 9 and eGFR using chronic kidney disease epidemiology collaboration (CKD-EPI) methods based on serum creatinine or cystatin C (adjusted for age, sex, and race). These endpoints, and other safety assessments, were summarized using descriptive statistics.
Adverse events (AEs) and any laboratory abnormalities recorded as AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA), Version 16.0.
This study is registered with clinicaltrials.gov, number NCT01363011.
Results:
Of the 71 screened patients, 33 were enrolled and received at least 1 dose of STB. The median duration of exposure to study drug was 61 weeks (Q1 to Q3: 58 to 72 weeks). The baseline characteristics are shown in Table 1 The overall safety findings were generally consistent with those of the Phase 3 studies. No treatment-emergent deaths were reported. Serious AEs were reported for 12% of patients (n=4):
increased blood creatine phosphokinase (n=1); infected cyst (n=1); right ventricular failure and A C C E P T E D lymphoma (both in the same patient; n=1); hepatitis C and Hodgkin's disease (both in the same patient; n=1). None were considered related to study drug except for the serious AE of increased blood creatinine phosphokinase. The most frequent AEs were diarrhea (30%); insomnia (21%);
and nausea and headache (each 18%). AEs considered related to study drug by the investigator were reported for 45% of subjects (15/33 subjects). The most frequently reported AEs considered related to study drug by the investigator were nausea (3 patients), and blurred vision, upper abdominal pain, vomiting, decreased glomerular filtration rate, hyperglycemia, headache, and insomnia (each reported for 2 patients).
Four patients (12%) discontinued study drug due to an AE. One patient discontinued due to hepatitis C and Hodgkin's disease. The other three patients discontinued due to renal AEs, two of whom met the protocol-defined criterion for potential discontinuation. All three patients had baseline CrCl between 50-55 mL/min and developed CrCL < 50mL/min without evidence of PRT. Only one patient had cystatin C-based eGFR < 50 mL/min/1.73m 2 at the time of discontinuation, which was pre-existing at baseline. CrCl returned to baseline after STB discontinuation in two patients; one patient did not have any post discontinuation data available. 
Increases in median values

Discussion:
This is the first study evaluating the efficacy and safety of STB in treatment naïve patients with mild to moderate renal impairment, who are considered to be at increased risk from a renal safety perspective. In these patients, STB achieved high rates of virologic suppression and was well tolerated with no new renal safety signals.
FTC and TDF, the two nucleos(t)ide reverse transcriptase inhibitors within STB, require dose adjustment in patients with CrCl < 50 mL/min. 12 However, EVG and COBI do not require dose adjustment in patients with renal impairment as they are primarily eliminated via hepatic metabolism. In a phase 1 study of EVG and COBI in patients with severe renal impairment (CrCl < 30 mL/min), no clinically relevant differences in EVG or COBI exposures were seen. 13 Importantly, the expected decrease in CrCl due to COBI resulted in the recommendation for initiating STB only in patients with CrCl ≥ 70 mL/min.
It is reassuring that no new or unexpected safety signals of STB were observed through 48 weeks in treatment naïve patients with mild to moderate renal impairment. STB was generally well tolerated and the safety findings were consistent with those observed in two large phase 3 registrational studies. Importantly, the changes in CrCl in patients with baseline CrCl < 70 mL/min were similar to those in patients with baseline CrCl ≥ 70 mL/min. The renal AEs that led to study drug discontinuation were generally consistent with the effects of COBI on serum creatinine, and none of the patients had laboratory findings indicative of PRT.
Despite the relatively small sample size, the strength of our study is the comprehensive assessment of renal safety in treatment naïve patients who were otherwise not eligible to initiate STB per the current prescribing recommendation due to low CrCl (i.e. 50 to < 70 mL/min).
In this first study of STB in treatment naïve patients with mild to moderate renal impairment, STB was generally safe, well tolerated and efficacious. Thus, the use of STB can be considered in treatment naïve patients with mild to moderate renal impairment with careful monitoring of renal function.
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